UNIVERSITY OF PENNSYLVANIA — SCHOOL OF MEDICINE Curriculum Vitæ

January 2012

Daniel Francis Heitjan, PhD

Office Address: Department of Biostatistics & Epidemiology

University of Pennsylvania School of Medicine

622 Blockley Hall, 423 Guardian Drive

Philadelphia, PA 19104-6021

Telephone: (215) 573-7328

FAX: (215) 573-4865

E-mail: dheitjan@upenn.edu

Education:

1977–1981 BSc University of Chicago (Mathematics)

1981–1982 MIT (Applied Mathematics)

1982–1984 MSc University of Chicago (Statistics)

1985 PhD University of Chicago (Statistics) Postgraduate Training and Fellowship Appointments: None Military Service: None Faculty Appointments:

1985–1988 Adjunct Assistant Professor, Department of Biomathematics, UCLA School of Medicine

1988–1992 Assistant Professor, Center for Biostatistics & Epidemiology, Penn State University College of Medicine

1992–1995 Associate Professor (tenured), Center for Biostatistics & Epidemiology, Penn State University College of Medicine

1995–1996 Visiting Associate Professor, Division of Biostatistics, School of Public Health, Columbia University

1996–2001 Associate Professor (tenured 1998), Division of Biostatistics, School of Public Health, Columbia University

2001–2002 Professor (tenured), Department of Biostatistics, Mailman School of Public Health, Columbia University

2002–present Professor (tenured), Department of Biostatistics & Epidemiology, University of Pennsylvania School of Medicine

2003–present Professor, Department of Statistics, Wharton School, University of Pennsylvania

2

Hospital and Administrative Appointments:

1995–2002 Director of Biostatistics, Herbert Irving Comprehensive Cancer Center, Columbia University

1996–2002 Director of Biostatistics, International Center for Health Outcomes and Innovation Research, Columbia University

2003– Director of Biostatistics, Abramson Cancer Center

2005–2007 Director of Graduate Studies in Biostatistics, CCEB

2007– Director of Educational Programs in Biostatistics, CCEB

2007– Chair, Graduate Group in Epidemiology & Biostatistics

Other Appointments: 1994–1995 Stanley S. Schor Visiting Scholar, Clinical Biostatistics, Merck & Co., Inc.

2002– Senior Scholar, Center for Clinical Epidemiology & Biostatistics (CCEB)

2002–present Member, Graduate Group in Epidemiology & Biostatistics, Biomedical Graduate Studies Program, UPenn School of Medicine

Specialty Certification: Not applicable Licensure: Not applicable Awards, Honors and Membership in Honorary Societies:

1977–1981 National Merit Scholar, University of Chicago

1977–1981 State of Michigan Legislative Scholar, University of Chicago

1984–1985 Warner-Lambert Fellow, Statistics Department, University of Chicago

1985 ENAR Spring Meeting Student Award Paper

1994 CTC and ATSDR Statistics Award

1994–1995 Stanley S. Schor Visiting Scholar, Merck Research Laboratories

1997 Elected a Fellow of the American Statistical Association

2001–2002 Program Chair, American Statistical Association Biometrics Section, 2002 Joint Statistical Meetings

2003–2006 Program Chair, 2005 Joint Statistical Meetings

2008–2010 Chair-Elect (2008), Chair (2009), Past Chair (2010), Biometrics Section, American Statistical Association

2009–2011 Elected member of Regional Committee, Eastern North American Region, International Biometric Society

2012–2014 President-Elect (2012), President (2013), Past President (2014), Eastern North American Region, International Biometric Society

3

Memberships in Professional and Scientific Societies (including offices held):

American Statistical Association 1982–present Member

1997 Elected Fellow

2002 Program Chair, Biometrics Section, Joint Statistical Meetings

2003–2005 Program Chair, 2005 Joint Statistical Meetings (JSM)

2003–2006 Member, Committee on Meetings

2004 Member, Task Force on the JSM

2008–2010 Chair-Elect, Chair, Past Chair, Biometrics Section Institute of Mathematical Statistics

1987–present Member International Biometric Society (Eastern North American Region)

1984–present Member 2009–2011 Elected member, Regional Committee 2012–2014 President-elect, President, Past President, ENAR

Society for Clinical Trials 1998–present Member

National Scientific Committees:

1989 National Cancer Institute (NCI): Ad hoc reviewer,

1992 Children’s Miracle Network Research Starter Grants

1992 National Institutes of Health (NIH): Consultant on review of RFA HD-92-09

1993 NIH: Member of review committee for RFA HD-93-07

1994 American Institute for Cancer Research: ad hoc reviewer

1996 NIH: Member of review committee for RFP CD-95-03

1997 NIH: Member of review committee for NIAID

1996 & 1998 National Science Foundation (NSF); ad hoc reviewer

1998 NIH: Member of review committee for RFP DK-98-04

1998–2000 Consortial Center for Chiropractic Research: Scientific reviewer

1998–2001 NIH: Ad hoc member, AIDS and Related Research (AARR6) Study Section

2001 NIH: Member of review committee for RFA AI-01-003

2001 NIH: Ad hoc member, AIDS and Related Research (AARR1) Study Section

2002 NIH: Member of review committee for RFA AI-01-018

2003 AHRQ: Ad hoc member, Health Care Technology and Decision Sciences (HCTDS) Study Section

2003 NIH: Ad hoc member, Clinical Oncology (CONC) Study Section

2003 NIH: Member of review committee for RFA HL-03-003

2003 MRC: Ad hoc reviewer

2003 NHLBI: Member, C-Reactive Protein Pilot Study Planning Committee

2003–2007 AHRQ: Regular member, HCTDS Study Section

2004–2006 NIH: Ad hoc reviewer, NCI P01 cluster

4

2004, 2005, 2008, 2009

NIH: Ad hoc reviewer, AIDS Clinical Studies and Epidemiology (ACE) Study Section

2004 NIH: Member of review committee for RFA CA-05-009

2005 NIH: Member of review committee for SPORE grants

2006 NIH: Ad hoc reviewer, ZRG1 ONC-B (02)

2007 ZonMW (Netherlands Organisation for Health Research and Development): Ad hoc reviewer, 3rd Prevention Programme

2007 NIH: Ad hoc reviewer, special emphasis panel, NIAID

2008 NIH: Invited participant, Workshop on “Barriers to Producing Well-Tested, User-Friendly Software for Cutting-Edge Statistical Methodology”, Rockville, MD

2008–2009 Susan G. Komen for the Cure Grants Program: Immunotherapies Peer Review Committee

2009 AHRQ: Invited participant, Workshop on “Centers for Medicare & Medicaid Services (CMS) Changes in Reimbursement for Hospital-Acquired Infections (HAIs): Setting a Research Agenda”, New York City

2010 DoD: Ad hoc reviewer, PRORP

2010 Advisory Board, “Functional Bowel Disorders in Chinese Medicine”, International Center for Research on Complementary and Alternative Medicine, University of Maryland, Baltimore.

Data and Safety Monitoring Boards: 1993–1994 Trials of Amiloride in cystic fibrosis, Glaxo Inc.

1997–2001 Study and Treatment of Post-Lyme Disease (STOP-LD), NIAID

2004–2005 DeBakey Bridge-to-Transplant and Destination LVAD Trials

2004–2010 Interventions to Improve Memory in Patients with MS (AIMS 2), NINDS

2004–2006 CAPTIVATE Trial, Sankyo

2004– Policosanol studies, Wyeth Consumer Healthcare

2005– Heartmate II Pivotal Study, Thoratec

2005– Studies of an obesity compound, Merck & Co., Inc.

2006–2008 ASA-STAT Trial, NHLBI

2006– Trials of a cancer compound, Centocor, Inc.

2008– Diabetes and Periodontal Therapy Trial (DPTT), Stony Brook University

Editorial Positions:

1994– Regular statistical reviewer, Annals of Internal Medicine

1995–2001 Associate Editor, Applications & Case Studies, Journal of the American Statistical Association

1996–2005 Member, Editorial Board, Statistics in Medicine

2001– Member, Board of Statistical Editors, Journal of the National Cancer Institute

2006– Associate Editor, Statistics in Biopharmaceutical Research

2008– Associate Editor, Clinical Trials

5

Referee Addiction

Referee American Journal of Epidemiology

Referee The American Statistician

Referee Anesthesiology

Referee Annals of Applied Statistics

Referee Annals of Statistics

Referee Annals of the Institute of Statistical Mathematics

Referee Applied Statistics

Referee Archives of General Psychiatry

Referee Australian and New Zealand Journal of Statistics

Referee BMC Medical Research Methodology

Referee Biometrical Journal

Referee Biometrics

Referee Biometrika

Referee Biostatistics

Referee Canadian Journal of Statistics

Referee Cancer Epidemiology, Biomarkers & Prevention

Referee Cancer Research

Referee Circulation

Referee Clinical Cancer Research

Referee Clinical Orthopædics and Related Research

Referee Clinical Trials

Referee Communications in Statistics

Referee Computational & Mathematical Methods in Medicine

Referee Computational Statistics and Data Analysis

Referee Contemporary Clinical Trials

Referee Controlled Clinical Trials

Referee Clinical Orthopaedics and Related Research

Referee ClinicoEconomics & Outcomes Research

Referee Current Controlled Trials in Cardiovascular Medicine

Referee Encyclopedia of Clinical Trials

Referee Expert Review of Pharmacoeconomics & Outcomes Research

Referee Health Economics

Referee Health Services and Outcomes Research Methodology

Referee Information Systems and Operational Research

Referee Journal of the American Statistical Association

Referee Journal of the American Medical Association

Referee Journal of Applied Statistical Science

Referee Journal of Applied Statistics

6

Referee Journal of Behavioral Medicine

Referee Journal of Biopharmaceutical Statistics

Referee Journal of Business and Economic Statistics

Referee Journal of Clinical Oncology

Referee Journal of Health Economics

Referee Journal of Multivariate Analysis

Referee Journal of the National Cancer Institute

Referee Journal of the Royal Statistical Society (Series B)

Referee Journal of Statistical Planning & Inference

Referee Lifetime Data Analysis

Referee Medical & Pediatric Oncology

Referee Medical Decision Making

Referee PharmacoEconomics

Referee PLoS Medicine

Referee Preventive Medicine

Referee Proceedings of the National Academy of Sciences

Referee Retina

Referee Scandinavian Journal of Statistics

Referee Science

Referee Sociological Methodology

Referee Soochow Journal of Mathematics

Referee Statistica Sinica

Referee Statistical Methodology

Referee Statistical Methods in Medical Research

Referee Statistical Modelling

Referee Statistical Papers

Referee Statistical Science

Referee Statistics in Medicine

Referee Survey Methodology

Referee Technometrics

Referee Transactions of the Society of Actuaries

Referee Tropical Medicine & International Health

Referee Value in Health

Reviewer for book publishers:

1991 Van Nostrand Reinhold

1991 Wadsworth Publishing Company

1993–1994 Duxbury Press

1994 Oxford University Press

7

1999 Springer-Verlag

1999 Harcourt/Academic Press

2003 Chapman & Hall/CRC

Academic and Institutional Committees:

UCLA School of Medicine, Department of Biomathematics

1985–1988 Department Computing Committee

1985–1988 Department Teaching Policy Committee

Penn State College of Medicine, Center for Biostatistics and Epidemiology (CBE) 1990–1992 CBE Faculty Hiring Committee (Chair)

1990–1994 College Library Advisory Committee

1990–1992 College CE Liaison Committee

1992–1993 Biomedical Research Building Dedication committee

1992–1995 Curriculum and Teaching Committee

1993–1995 CBE Research Computing Advisory Committee

Columbia University, Department of Biostatistics

1995–2002 Cancer Center Protocol Review Committee, (vice-chair, 2001; chair 2002)

1996–2002 Doctoral Program Subcommittee on Biostatistics

1996–1997 Committee to develop an MS track in clinical research methods

1997–2002 Cancer Center Executive Committee

1998–2002 Cancer Committee, Tumor Registry Oversight Committee

1998–2001 Office of Clinical Trials Core Research Computer Committee

University of Pennsylvania, Department of Biostatistics & Epidemiology

2002– Chair, Biostatistics Graduate Admission Committee

2003– Department Committee on Appointments & Promotions

2003–2010 CCEB Seminar Committee

2005–2007 Director of Graduate Studies, Biostatistics

2005–2007 Biomedical Graduate School, Biomedical Advisory Committee

2005–2006 Ad hoc Committee to review the Graduate Group in Neuroscience

2006–2009 Hearings List, Faculty Grievance Commission, Faculty Senate

2007– Director of Educational Programs in Biostatistics

2008– Chair, Graduate Group in Epidemiology & Biostatistics

Major Academic and Clinical Teaching Responsibilities:

University of Chicago

Spring 1985 Statistics 2000 (Elementary Statistics); 30 contact hours; 35 students University of California Los Angeles (UCLA)

Fall 1986 & 1987

Biomathematics 170A (Introductory Biomathematics); 30 contact hours; 15 students/year

8

Penn State University

Spring 1989, 1991, 1993

Behavioral Science 508 (Experimental Design); 30 contact hours; 10–15 students per year

Fall 1991 – Spring 1992

Statistics 580 (Statistical Consulting); Responsible for four contact hours (out of 45), approximately 15 students

Columbia University

Spring 1996, Fall 1996,

Fall 1999

Biostatistics P6104 (Introduction to Statistical Methods); 45 contact hours; 40 students (spring '96); 25 students (fall '96); 170 students (fall ’99)

1996– Training grant in Cancer Epidemiology, Biostatistics and Environmental Health; Professor Al Neugut, Division of Epidemiology, PI

Fall 1996, Spring 1999

Law L6248 (Statistics for Lawyers); Michael Finkelstein, instructor; Responsible for three contact hours; 10–15 students

Spring 1997, 1998, 1999, 2001, 2002

Biostatistics P8116 (Design of Medical Experiments, cross-listed as Statistics W4327); 45 contact hours; 15–25 students

Spring 1999 Epidemiology P8401 (Pharmacoepidemiology); Alfred I. Neugut, instructor; responsible for 1.5 contact hours (out of 45); approximately 20 students

University of Pennsylvania

Spring 2003 BSTA 782 (Incomplete Data); 45 contact hours; 5 students

Spring 2004 BSTA 621/STAT 512 (Inference I); 45 contact hours; 7 students

Spring 2005 BSTA 782 (Incomplete Data); 45 contact hours; 8 students

Spring 2006 BSTA 659 (Design of Biomedical Studies); course director with Kevin Lynch; 45 contact hours; 6 students

Spring 2007 BSTA 659 (Design of Biomedical Studies); 45 contact hours; 7 students

Spring 2008 BSTA 659 (Design of Biomedical Studies); 45 contact hours; 7 students

Summer 2008 EPID 645 (Cancer Epidemiology, Biomarkers & Prevention); Kathryn Schmitz, coordinator; 1 contact hour; 8 students.

Spring 2009 BSTA 659 (Design of Biomedical Studies); 45 contact hours; 7 students

BSTA 656 (Longitudinal Data Analysis); Benjamin French, coordinator; 1 contact hour; 7 students.

Summer 2009 EPID 645 (Cancer Epidemiology, Biomarkers & Prevention); Kathryn Schmitz, coordinator; 1 contact hour; ~5 students.

Summer 2010 EPID 645 (Cancer Epidemiology, Biomarkers & Prevention); Kathryn Schmitz, coordinator; 1 contact hour; ~5 students.

Spring 2011 BSTA 659 (Design of Biomedical Studies); 45 contact hours; 7 students

Spring 2012 BSTA 657 (Design of Biomedical Studies — Part 1); 22.5 contact hours

Spring 2012 BSTA 799 (Advanced Topics in Biostatistics — Incomplete Data); 22.5 contact hours

9

Doctoral Students Trained

2001 Nandita Mitra, PhD, Biostatistics, Columbia. Assistant Professor, Department of Biostatistics & Epidemiology, Penn.

2001 Guoguang Julie Ma, PhD, Biostatistics, Columbia. Biostatistician, Amgen. Van Ryzin Award for best PhD dissertation in the Department.

2003 Hui Xie, PhD, Biostatistics, Columbia. Assistant Professor, Division of Epidemiology & Biostatistics, School of Public Health, U. of Illinois at Chicago.

2004 Huiling Li, DrPH, Biostatistics, Columbia. Biostatistician, Sanofi-Aventis. Fertig Award for best DrPH dissertation in the Department.

2004 Jiameng Zhang, PhD, Biostatistics, Penn. Senior Biostatistician, Genentech. Winegrad Award for best dissertation in the Department.

2004 Gui-Shuang Ying, PhD, Biostatistics, Penn. Assistant Professor, Ophthalmology, Penn.

2005 Clara Yuri Kim, PhD, Biostatistics, Penn. Statistical Reviewer, CDER, FDA.

2006 J. Mark Donovan, PhD, Biostatistics, Penn. Statistician, Bristol-Myers Squibb. Winegrad Award for best dissertation in the Department.

2006 Tao Liu, PhD, Biostatistics, Penn. Assistant Professor, Center for Statistical Sciences, Brown University.

2008 Carin Joo Kim, PhD, Biostatistics, Penn. Statistical Reviewer, CDER, FDA.

2009 Mengye Guo, PhD, Biostatistics, Penn. Research Scientist, Collaborative Health Studies Coordinating Center, University of Washington.

2009 Hao Wang, PhD, Biostatistics, Penn. Assistant Professor, Division of Oncology Biostatistics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University.

2010 Yimei Li, PhD, Biostatistics, Penn. Instructor, Department of Pediatrics, CHOP and Penn.

I have served on the dissertation committees of numerous other students in Biostatistics, Epidemiology, Environmental Health Sciences, Medical Informatics, and Statistics at Columbia; and Statistics at Penn.

Lectures by Invitation (last five years):

1/2008 ICER vs. INHB: The statistical issues. International Conference on Health Research and Policy, Philadelphia, PA.

3/2008 Sensitivity analysis of causal inference in a clinical trial subject to crossover. ASA Connecticut Chapter Annual Meeting, Danbury, CT.

8/2008 Coarse data. Introductory Overview Lecture. Joint Statistical Meetings, Denver, CO. 6/2009 Diagnosing sensitivity to nonignorability. Celebrating 75 Years of Statistics at Iowa State,

Ames, IA. 8/2010 Prediction of individual long-term outcomes from a multivariate cure-mixture frailty

model. Joint Statistical Meetings, Vancouver, BC. (With Yimei Li and E. Paul Wileyto; to be presented by DFH.)

9/2010 Sensitivity to missing and otherwise incomplete data in clinical trials. Workshop on “Clinical Trials: Past, Present and Future”. Division of Cardiovascular Sciences, NHLBI, Bethesda, MD.

6/2011 Model-based analysis of heaped longitudinal cigarette count data in smoking cessation

10

trials. International Chinese Statistical Association Applied Statistics Symposium, New York, NY. (With Sandra Griffith, Yimei Li, Hao Wang and E. Paul Wileyto; presented by DFH.)

8/2011 Model-based analysis of heaped longitudinal cigarette count data in smoking cessation trials. Joint Statistical Meetings, Miami, FL, 11.08. (With Sandra Griffith, Yimei Li, Hao Wang and E. Paul Wileyto; presented by DFH.)

10/2011 Real-time prediction in clinical trials: A statistical history of REMATCH. Korean Region of the International Biometric Society, Seoul, South Korea.

Invited Seminars (last five years):

11/2006 Measuring sensitivity to nonignorable coarsening. Statistics, Rutgers University, Piscataway, NJ.

8/2007 Recovering correct inferences by modeling heaped data. Biostatistics, University of Alabama at Birmingham.

4/2008 Bayesian estimation of cost-effectiveness from censored data. Biostatistics, University of Illinois, Chicago.

7/2008 Statistical analysis for cost-effectiveness studies. Amgen, Inc. Thousand Oaks, CA. 6/2010 When should we be concerned about nonignorably missing data? Biostatistics, University

of Maryland, Baltimore. 9/2010 Sensitivity to missing and otherwise incomplete data in clinical trials. Biostatistics,

University of Pennsylvania, Philadelphia, PA. 9/2011 Truth and memory: Analysis of self-reported cigarette count data in smoking cessation

trials. Statistics, Cornell University, Ithaca, NY. 10/2011 Truth and memory: Analysis of self-reported cigarette count data in smoking cessation

trials. Statistics, Seoul National University, Seoul, South Korea. 10/2011 When should we be concerned about nonignorably missing data? Statistics, Korea

University, Seoul, South Korea. 11/2011 When should we be concerned about nonignorably missing data? Public Health Sciences,

Fred Hutchinson Cancer Research Center, Seattle, WA. 11/2011 Real-time prediction in clinical trials: A statistical history of REMATCH. Biostatistics,

University of Washington, Seattle, WA. Organizing roles in Scientific Meetings:

1990 American Statistical Association: Organized two roundtable luncheons for the Biometrics Section at the Joint Statistical Meetings in Atlanta, GA

1993 American Statistical Association: Organized an invited session, "Biomedical Applications of Multiple Imputation", for the Joint Statistical Meetings in San Francisco

1995 International Biometric Society: Organized an invited session, "Statistical Applications in Medical Basic Science”, for the ENAR Meeting in Richmond, VA

1997 International Biometric Society: Organized an invited session, "Phase I Clinical Trials”, for the WNAR meeting in San Diego, CA

2002 American Statistical Association: Program Chair, Biometrics Section, 2002 Joint Statistical Meetings in New York, NY

2005 American Statistical Association: Program Chair, 2005 Joint Statistical Meetings in Minneapolis, MN

2004–2006 Committee on Meetings, American Statistical Association 2008–2010 American Society for Clinical Oncology: Member of Scientific Program Committee,

11

2008 meeting (Chicago, IL) and 2009 meeting (Orlando, FL) 2011 International Chinese Statistical Association: Organized two invited sessions for the

Applied Statistics Symposium. 2012 Thomas Ten Have Symposium on Statistics in Mental Health Research: Organizer.

Bibliography:

Research Publications (peer reviewed):

1. Ojo-Amaize, E., Nishanian, P., Keith, D. E. Jr., Houghton, R. L., Heitjan, D. F., Fahey, J. L., Giorgi, J. V. (1987). HIV antibodies in human sera induce cell-mediated lysis of HIV-infected cells: Possible association between capacity to induce lysis and presence of antibodies to HIV envelope proteins. Journal of Immunology 139, 2458–2463.

2. Tobler, A., Munker, R., Heitjan, D. and Koeffler, H. P. (1987). In vitro interaction of recombinant tumor necrosis factor alpha and all-trans-retinoic acid with normal and leukemic hematopoietic cells. Blood 70, 1940–1946.

3. Koeffler, H. Phillip, Heitjan, Daniel, Mertelsmann, Roland, Kolitz, Jonathan E., Schulman, Philip, Itri, Loretta, Gunter, Patricia and Besa, Emmanuel (1988). Randomized study of 13-cis-retinoic acid v placebo in the myelodysplastic disorders. Blood 71, 703–708.

4. Heitjan, Daniel F. (1989). Inference from grouped continuous data: A review (with discussion). Statistical Science 4, 164–183.

5. Martinez-Maza, Otoniel, Mitsuyasu, Ronald T., Miles, Steven A., Giorgi, Janis V., Heitjan, Daniel F., Sherwin, Stephen A. and Fahey, John L. (1989). Gamma-interferon-induced monocyte major histocompatibility complex class II antigen expression in individuals with acquired immune deficiency syndrome. Cellular Immunology 123, 316–324.

6. Ojo-Amaize, Emmanuel, Nishanian, Parunag G., Heitjan, Daniel F., Rezai, Alex, Esmail, Imu, Korns, Elizabeth, Detels, Roger, Fahey, John and Giorgi, Janis V. (1989). Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression. Journal of Clinical Immunology 9, 454–461.

7. Gascho, Joseph A., Copenhaver, Gary L. and Heitjan, Daniel F. (1990). Systolic thickening increases from subepicardium to subendocardium. Cardiovascular Research 24, 777–780.

8. Heitjan, Daniel F. and Rubin, Donald B. (1990). Inference from coarse data via multiple imputation with application to age heaping. Journal of the American Statistical Association 85, 304–314.

9. Santen, R. J., Manni, A., English, H. F. and Heitjan, D. (1990). Androgen-primed chemotherapy-experimental confirmation of efficacy. Journal of Steroid Biochemistry and Molecular Biology 37, 1115–1120.

10. Wengrovitz, Mark, Atnip, Robert G., Gifford, Robert R. M., Neumyer, Marsha M., Heitjan, Daniel F. and Thiele, Brian L. (1990). Wound complications of autogenous subcutaneous infrainguinal arterial bypass surgery: Predisposing factors and management (with discussion). Journal of Vascular Surgery 11, 156–163.

11. English, Hugh F., Heitjan, Daniel F., Lancaster, Scott and Santen, Richard J. (1991). Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. Cancer Research 51, 1760–1765.

12. Heitjan, Daniel F. (1991). Generalized Norton-Simon models of tumor growth. Statistics in Medicine 10, 1075–1088.

13. Heitjan, Daniel F. (1991). Nonlinear modeling of serial immunologic data: A case study. Journal of the American Statistical Association 86, 891–898.

14. Heitjan, Daniel F. (1991). Regression with bivariate grouped data. Biometrics 47, 549–562. 15. Heitjan, Daniel F. and Little, Roderick J. A. (1991). Multiple imputation for the Fatal Accident

Reporting System. Applied Statistics 40, 13–29.

12

16. Heitjan, Daniel F. and Rubin, Donald B. (1991). Ignorability and coarse data. Annals of Statistics 19, 2244–2253.

17. Houts, Peter S., Wojtkowiak, Sandra L., Simmonds, Mary A., Weinberg, Gene B. and Heitjan, Daniel F. (1991). Using a state cancer registry to increase screening behaviors of sisters and daughters of breast cancer patients. American Journal of Public Health 81, 386–388.

18. Heitjan, Daniel F., Derr, Janice A. and Satyaswaroop, Pondichery G. (1992). The multi-site tumor transplantation model for human endometrial carcinoma: A statistical evaluation. Cell Proliferation 25, 193–203.

19. Heitjan, Daniel F., Houts, Peter S. and Harvey, Harold A. (1992). A decision-theoretic evaluation of early stopping rules. Statistics in Medicine 11, 673–683.

20. Williams, Gerald D., Palmer, Charles, Heitjan, Daniel F. and Smith, Michael B. (1992). Allopurinol preserves cerebral energy metabolism during perinatal hypoxia-ischemia: A 31P NMR study in unanesthetized immature rats. Neuroscience Letters 144, 103–106.

21. Williams, Gerald D., Palmer, Charles, Roberts, Rebecca L., Heitjan, Daniel F. and Smith, Michael B. (1992). 31P NMR spectroscopy of cerebral hypoxic-ischemic injury: A model to evaluate neuroprotective drugs in neonates. NMR in Biomedicine 5, 145–153.

22. Yager, Jerome Y., Heitjan, Daniel F., Towfighi, Javad and Vannucci, Robert C. (1992). Effect of insulin-induced and fasting hypoglycemia on perinatal hypoxic-ischemic brain damage. Pediatric Research 31, 138–142.

23. Heitjan, Daniel F. (1993). Ignorability and coarse data: Some biomedical examples. Biometrics 49, 1099–1109.

24. Heitjan, Daniel F., Manni, Andrea and Santen, Richard J. (1993). Statistical analysis of in vivo tumor growth experiments. Cancer Research 53, 6042–6050.

25. Mawhinney, Helen, Spector, Sheldon L., Heitjan, D., Kinsman, R. A., Dirks, J. F. and Pines, I. (1993). As-needed medication use in asthma. Usage patterns and patient characteristics. Journal of Asthma 30, 61–71.

26. Palmer, Charles, Towfighi, Javad, Roberts, Rebecca L. and Heitjan, Daniel F. (1993). Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7 day old rats. Pediatric Research 33, 405–411.

27. Smith, Philip J. and Heitjan, Daniel F. (1993). Testing and adjusting for departures from nominal dispersion in generalized linear models. Applied Statistics 42, 31–41.

28. Heitjan, Daniel F. (1994). Ignorability in general incomplete-data models. Biometrika 81, 701–708. 29. Heitjan, Daniel F. and Landis, J. Richard (1994). Assessing secular trends in blood pressure: A multiple-

imputation approach. Journal of the American Statistical Association 89, 750–759. 30. Manni, Andrea, Badger, Betty, Wei, Lisa, Zaenglein, Andrea, Grove, Rhea, Khin, Sonny, Heitjan, Daniel

F., Shimasaki, Shunichi and Ling, Nicholas (1994). Hormonal regulation of IGF-II and IGF binding protein expression by breast cancer cells in vivo: Evidence for stromal-epithelial interactions. Cancer Research 54, 2934–2942.

31. Mujsce, Dennis J., Towfighi, Javad, Heitjan, Daniel F. and Vannucci, Robert C. (1994). Differences in intra-ischemic temperature influence neurologic outcome after hypothermic circulatory arrest in newborn dogs. Stroke 25, 1433–1442.

32. Towfighi, Javad, Housman, Cathy, Vannucci, Robert C. and Heitjan, Daniel F. (1994). Effect of unilateral perinatal hypoxic-ischemic brain damage on the gross development of the opposite hemisphere. Biology of the Neonate 65, 108–118.

33. Towfighi, J., Housman, C., Heitjan, D. F., Vannucci, R. C. and Yager, J. Y. (1994). The effect of focal cerebral cooling on perinatal hypoxic-ischemic brain damage. Acta Neuropathologica 87, 598–604.

34. Cataltepe, Oguz, Barron, Todd F., Heitjan, Daniel F., Vannucci, Robert C. and Towfighi, Javad (1995). Effect of hypoxia/ischemia on bicuculline-induced seizures in immature rats: Behavioral and

13

electrocortical phenomena. Epilepsia 36, 396–403. 35. Cataltepe, Oguz, Vannucci, Robert C., Heitjan, Daniel F. and Towfighi, Javad (1995). Effect of status

epilepticus on hypoxic-ischemic brain damage in the immature rat. Pediatric Research 38, 251–257. 36. Heitjan, Daniel F. (1995). Bayesian analysis of a protocol for sampling preserved tumor specimens.

Journal of the American Statistical Association 90, 38–44. 37. Heitjan, Daniel F. and Kunselman, Susan (1995). Time until first significant difference in in vivo tumor

growth experiments. In Vivo 9, 7–9. 38. Manni, Andrea, Wechter, Rita, Wei, Lisa, Heitjan, Daniel and Demers, Laurence (1995). Phenotypic

features of breast cancer cells overexpressing ornithine-decarboxylase. Journal of Cellular Physiology 163, 129–136.

39. Masamura, Shigeru, Santner, Steven J., Heitjan, Daniel F. and Santen, Richard J. (1995). Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80, 2918–2925.

40. Vannucci, Robert C., Towfighi, Javad, Heitjan, Daniel F. and Brucklacher, Robert M. (1995). Carbon dioxide protects the perinatal brain from hypoxic-ischemic damage: An experimental study in the immature rat. Pediatrics 95, 868–874.

41. Begemann, Martin, Kashimawo, Sharafadeen A., Choi, Yu-jeong A., Kim, Susan, Christiansen, Kim M., Duigou, Gregg, Mueller, Marcel, Schieren, Ira, Ghosh, Subrata, Fabbro, Doriano, Lampen, Nina M., Heitjan, Daniel F., Schiff, Peter B., Bruce, Jeffrey N., and Weinstein, I. Bernard (1996). Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter. Clinical Cancer Research 2, 1017–1030.

42. Heitjan, Daniel F. and Basu, Srabashi (1996). Distinguishing "missing at random" and "missing completely at random". The American Statistician 50, 207–213. .

43. Marcus, Lee S., Hart, Douglas, Packer, Milton, Yushak, Madeline, Medina, Norma, Danziger, Robert S., Heitjan, Daniel F. and Katz, Stuart D. (1996). Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: A double-blind, placebo-controlled, randomized crossover trial. Circulation 94, 3184–3189.

44. Ennis, Ronald D., Katz, Aaron E., de Vries, Glen M., Heitjan, Daniel F., O'Toole, Kathleen M., Rubin, Mark, Buttyan, Ralph, Benson, Mitchell C., Schiff, Peter B. (1997). Detection of circulating prostate cancer cells via an enhanced reverse transcriptase-polymerase chain reaction in patients with early stage prostate carcinoma: Independence from other pre-treatment characteristics. Cancer 79, 2402–2408.

45. Goluboff, Erik T., Heitjan, Daniel F., deVries, Glen M., Katz, Aaron E. and Olsson, Carl A. (1997). Pre-treatment prostate-specific antigen doubling times: Utility in patients before radical prostatectomy (with discussion). Journal of Urology 158, 1876–1879.

46. Heitjan, Daniel F. (1997). Bayesian interim analysis of phase II cancer clinical trials. Statistics in Medicine 16, 1791–1802.

47. Heitjan, Daniel F. (1997). Ignorability, sufficiency and ancillarity. Journal of the Royal Statistical Society, Series B 59, 375–381.

48. Heitjan, Daniel F. and Sharma, Divakar (1997). Modeling repeated-series longitudinal data. Statistics in Medicine 16, 347–355.

49. Papadopoulos, K. P., Ayello, J., Tugulea, S., Heitjan, D. F., Williams, C., Reiss, R., Vahdat, L. T., Suciu-Foca, N., Antman, K. H. and Hesdorffer, C. S. (1997). Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support. Journal of Hematotherapy 6, 61–68.

50. Begemann, Martin, Kashimawo, Sharafadeen A., Heitjan, Daniel F., Schiff, Peter B., Bruce, Jeffrey N. and Weinstein, I. Bernard (1998). Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. Anticancer Research 18, 2275–2282.

14

51. Begemann, Martin, Kashimawo, Sharafadeen A., Lunn, Ruth M., Delohery, Thomas, Choi, Yu-Jeong A., Kim, Susan, Heitjan, Daniel F., Santella, Regina M., Schiff, Peter B., Bruce, Jeffrey N. and Weinstein, I. Bernard (1998). Growth inhibition induced by Ro 31-8220 and Calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase. Anticancer Research 18, 3139–3152.

52. Ennis, Ronald D., Malyszko, Bozena K., Heitjan, Daniel F., Rubin, Mark A., O'Toole, Kathleen M. and Schiff, Peter B. (1998). Changes in biochemical disease free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external beam radiotherapy. International Journal of Radiation Oncology, Biology, Physics 41, 511–517.

53. Ennis, Ronald D., Malyszko, Bozena, Rescigno, John, Whitman, Adam E., Heitjan, Daniel F., O'Toole, Kathleen M., Rubin, Mark and Schiff, Peter B. (1998). Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: A proposal based on patients treated with external beam radiotherapy. Urology 51, 265–270.

54. Goluboff, Erik T., Saidi, James A., Mazer, Sean, Bagiella, Emilia, Heitjan, Daniel F., Benson, Mitchell C. and Olsson, Carl A. (1998). Urinary continence after radical prostatectomy: The Columbia experience. Journal of Urology 159, 1276–1280.

55. Shabsigh, Ahmad, Chang, David T., Heitjan, Daniel F., Kiss, Alex, Olsson, Carl A., Puchner, Peter J. and Buttyan, Ralph (1998). Rapid reduction in blood flow to the rat ventral prostate gland after castration. Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. The Prostate 36, 201–206.

56. Vahdat, L. T., Papadopoulos, K., Balmaceda, C., McGovern, T., Dunleavy, J., Kaufman, E., Fung, B., Garrett, T., Savage, D., Tiersten, A., Ayello, J., Bagiella, E., Heitjan, D., Antman, K. and Hesdorffer, C. (1998). Phase I trial of sequential high-dose chemotherapy with escalating-dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Clinical Cancer Research 4, 1689–1695.

57. Antman, Karen H., Heitjan, Daniel F. and Hortobagyi, Gabriel N. (1999). High-dose chemotherapy for breast cancer. Journal of the American Medical Association 282, 1701–1703.

58. Goluboff, Erik T., Shabsigh, Ahmad, Saidi, James A., Weinstein, I. Bernard, Mitra, Nandita, Heitjan, Daniel, Piazza, Gary A., Pamukcu, Rifat, Buttyan, Ralph and Olsson, Carl A. (1999). Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53, 440–445.

59. Grann, Victor R., Whang, William, Jacobson, Judith S., Heitjan, Daniel F., Antman, Karen H. and Neugut, Alfred I. (1999). Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. Journal of Clinical Oncology 17, 494–500.

60. Heitjan, Daniel F. (1999). Causal inference in a clinical trial: A comparative example. Controlled Clinical Trials 20, 309–318.

61. Heitjan, Daniel F. (1999). Ignorability and bias in clinical trials. Statistics in Medicine 18, 2421–2434. 62. Heitjan, Daniel F., Moskowitz, Alan J. and Whang, William (1999). Bayesian estimation of cost-

effectiveness ratios from clinical trials. Health Economics 8, 191–201. 63. Heitjan, Daniel F., Moskowitz, Alan J. and Whang, William (1999). Problems with interval estimation of

the incremental cost-effectiveness ratio. Medical Decision Making 19, 9–15. (Accompanying editorial: Stinnett, Aaron A. (1999). Is it really so bad to be unambiguously inefficient? The role of dominance in stochastic cost-effectiveness analysis. Medical Decision Making 19, 102–103.)

64. Hripcsak, George, Kuperman, Gilad J., Friedman, Carol and Heitjan, Daniel F. (1999). A reliability study for evaluating information extraction from radiology reports. Journal of the American Medical Informatics Association 6, 143–150.

65. Knell, Ellen R., Presant, Cary A., Grann, Victor R., Whang, William, Jacobson, Judith S., Heitjan, Daniel F., Antman, Karen H. and Neugut, Alfred I. (1999). Re-evaluation of the benefits of BRCA1/2 testing. Journal of Clinical Oncology 17, 1962.

15

66. Longley, B. Jack, Metcalfe, Dean D., Tharp, Michael, Wang, Xiaomei, Tyrrell, Lynda, Lu, Suh-zhuang, Heitjan, D. and Ma, Yongsheng (1999). Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proceedings of the National Academy of Sciences of the USA 96, 1609–1614.

67. Petrylak, Daniel P., Macarthur, Robert B., O'Connor, John, Shelton, Gary, Judge, Timothy, Balog, Joshua, Pfaff, Charles, Bagiella, Emilia, Heitjan, Daniel, Fine, Robert, Zuech, Nancy, Sawczuk, Ihor, Benson, Mitchell, Olsson, Carl A. (1999). Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Journal of Clinical Oncology 17, 958–967.

68. Rose, Eric A., Moskowitz, Alan J., Packer, Milton, Sollano, Josephine A., Williams, Deborah L., Tierney, Anita R., Heitjan, Daniel F., Meier, Paul, Ascheim, Deborah Davis, Levitan, Ronald G., Weinberg, Alan D., Stevenson, Lynn Warner, Shapiro, Peter A., Lazar, Ronald M., Watson, John, Goldstein, Daniel and Gelijns, Annetine C. for the REMATCH investigators (1999). The REMATCH Trial: Rationale, design and endpoints. Annals of Thoracic Surgery 67, 723–730.

69. Shabsigh, Ahmad, Tanji, Nozomu, D'Agati, Vivette, Rubin, Mark, Goluboff, Erik T., Heitjan, Daniel, Kiss, Alex and Buttyan, Ralph (1999). Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 140, 1920–1926.

70. Sollano, Josephine A., Gelijns, Annetine C., Moskowitz, Alan J., Heitjan, Daniel F., Cullinane, Suzanne, Saha, Ted, Chen, Jonathan M., Roohan, Patrick J., Reemtsma, Keith, and Shields, Eileen P. (1999). Volume-outcome relationships in cardiovascular surgery: New York State, 1990–1995. Journal of Thoracic and Cardiovascular Surgery 117, 419–430.

71. Vitale, Michael G., Krant, Jessica J., Gelijns, Annetine C., Heitjan, Daniel F., Arons, Raymond R., Bigliani, Louis U. and Flatow, Evan L. (1999). Geographic variations in the rates of operative procedures involving the shoulder, including total shoulder replacement, humeral head replacement, and rotator cuff repair. Journal of Bone and Joint Surgery 81-A, 763–772.

72. Whang, William, Sisk, Jane E., Heitjan, Daniel F. and Moskowitz, Alan J. (1999). Probabilistic sensitivity analysis in cost-effectiveness: An application from a study of vaccination against pneumococcal bacteremia in the elderly. International Journal of Technology Assessment in Health Care 15, 763–772.

73. Bagiella, Emilia, Sloan, Richard P. and Heitjan, Daniel F. (2000). Mixed effects models in psychophysiology. Psychophysiology 37, 13–20.

74. Grann, Victor R., Jacobson, Judith S., Whang, William, Hershman, Dawn, Heitjan, Daniel F., Antman, Karen H. and Neugut, Alfred I. (2000). Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2 positive women: A decision analysis. The Cancer Journal 6, 13–20.

75. Grann, Victor R., Sundararajan, Vijaya, Jacobson, Judith S., Whang, William, Heitjan, Daniel F., Antman, Karen H. and Neugut, Alfred I. (2000). Decision analysis of tamoxifen for the prevention of invasive breast cancer. The Cancer Journal 6, 169–178.

76. Heitjan, Daniel F. (2000). Fieller's method and net health benefits. Health Economics 9, 327–335. 77. Savage, D. G., Rule, S. A. J., Tighe, M., Garrett, T. J., Oster, M. W., Lee, R. T., Ruiz, J., Heitjan, D.,

Keohan, M. L., Flamm, M. and Johnson, S. A. (2000). Gemcitabine for relapsed or resistant lymphoma. Annals of Oncology 11, 595–597.

78. Bagiella, Emilia and Heitjan, Daniel F. (2001). Predicting analysis times in randomized clinical trials. Statistics in Medicine 20, 2055–2063.

79. Hoh, Josephine, Heitjan, Daniel F., Mérette, Chantal and Ott, Jurg (2001). Ascertainment and anticipation in family studies. Human Heredity 51, 23–26.

80. Joe, Andrew K., Arber, Nadir, Bose, Shikha, Heitjan, Daniel, Zhang, Yan, Weinstein, I. Bernard and Hibshoosh, Hanina (2001). Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer. Anticancer Research 21, 3535–3539.

81. Mitra, Nandita, Schnabel, Freya R., Neugut, Alfred I. and Heitjan, Daniel F. (2001). Estimating the

16

effect of an intensive screening and surveillance program on stage of breast cancer at diagnosis. Cancer 91, 1709–1715.

82. Rose, Eric A., Gelijns, Annetine C., Moskowitz, Alan J., Heitjan, Daniel F., Stevenson, Lynne W., Dembitsky, Walter, Long, James W., Ascheim, Deborah D., Tierney, Anita R., Levitan, Ronald G., Watson, John T. and Meier, Paul for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group (2001). Long-term use of a left ventricular assist device for end-stage heart failure. New England Journal of Medicine 345, 1435–1443. (Accompanying editorial: Jessup, Mariell (2001). Mechanical cardiac-support devices – dreams and devilish details. New England Journal of Medicine 345, 1490–1493.) (PMID11794191)

83. Chuang, Jen-Hsiang, Hripcsak, George and Heitjan, Daniel F. (2002). Design and analysis of controlled trials in naturally clustered environments: Implications for medical informatics. Journal of the American Medical Informatics Association 9, 230–238.

84. Grann, Victor R., Jacobson, Judith S., Thomason, Dustin, Hershman, Dawn, Heitjan, Daniel F. and Neugut, Alfred I. (2002). Effects of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations—2001: An updated decision analysis. Journal of Clinical Oncology 20, 2520–2529.

85. Hershman, Dawn, Sundararajan, Vijaya, Jacobson, Judith S., Heitjan, Daniel F., Neugut, Alfred I. and Grann, Victor R. (2002). Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: A cost-effectiveness analysis. Journal of Clinical Oncology 20, 9–16. (Accompanying editorial: Jordan, V. Craig and Morrow, Monica (2002). Chemoprevention of breast cancer: A model for change. Journal of Clinical Oncology 20, 1–3.)

86. Hripcsak, George and Heitjan, Daniel F. (2002). Measuring agreement in medical informatics reliability studies. Journal of Biomedical Informatics 35, 99–110.

87. Neugut, Alfred I., Fleischauer, Aaron T., Sundararajan, Vijaya, Mitra, Nandita, Heitjan, Daniel F., Jacobson, Judith S. and Grann, Victor R. (2002). Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: A population-based study. Journal of Clinical Oncology 20, 2643–2650.

88. Sundararajan, Vijaya, Mitra, Nandita, Jacobson, Judith S., Grann, Victor R., Heitjan, Daniel F. and Neugut, Alfred I. (2002). Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Annals of Internal Medicine 136, 349–357.

89. Savage, David G., Cohen, Neil S., Hesdorffer, Charles S., Heitjan, Daniel, Oster, Martin W., Garrett, Thomas J., Bar, Michael, del Prete, Salvatore, March, Robert, Lonberg, Mathew, Talbot, Susan, Mears, J. Gregory, Flamm, Michael, Taub, Robert N. and Nichols, Gwen (2003). Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leukemia and Lymphoma 44, 477–481.

90. Smith, Steven Jay, Neugut, Alfred, Heitjan, Daniel F., Forde, Kenneth, Holt, Peter, Santella, Regina M., Jiin-chyuan, Luo, Carney, Walter, Ward, Llewelyn and Brandt-Rauf, Paul W. (2003). In situ quantification of aberrant p53 in colorectal neoplasia. Biomarkers 8, 311–332.

91. Canter, Robert J., Zhou, Rong, Kesmodel, Susan B., Zhang, Yawei, Heitjan, Daniel F., Glickson, Jerry D., Leeper, Dennis B. and Fraker, Douglas L. (2004). Meta-iodobenzylguanidine (MIBG) and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. Annals of Surgical Oncology 11, 265–273.

92. Gustafson, Karen S., Furth, Emma E., Heitjan, Daniel F., Fansler, Zoya B. and Clark, Douglas P. (2004). DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: An approach that utilizes receiver-operating characteristics analysis. Cancer 102, 259–268.

93. Heitjan, Daniel F. and Li, Huiling (2004). Bayesian estimation of cost-effectiveness: An importance-sampling approach. Health Economics 13, 191–198.

94. Heitjan, Daniel F., Kim, Clara Yuri and Li, Huiling (2004). Bayesian estimation of cost-effectiveness from censored data. Statistics in Medicine 23, 1297–1309.

17

95. Ma, Guoguang and Heitjan, Daniel F. (2004). Sensitivity to nonignorability in frequentist inference. Chapter 16 in Applied Bayesian Modeling and Causal Inference from Incomplete-Data Perspectives, edited by Andrew Gelman and Xiao-Li Meng. New York: Wiley.

96. Troxel, Andrea, Ma, Guoguang and Heitjan, Daniel F. (2004). An index of local sensitivity to nonignorability. Statistica Sinica 14, 1221–1237.

97. Xie, Hui and Heitjan, Daniel F. (2004). Sensitivity analysis of causal inference in a clinical trial subject to crossover. Clinical Trials 1, 21–30.

98. Ying, Gui-Shuang, Heitjan, Daniel F. and Chen, Tai-Tsang (2004). Nonparametric prediction of analysis times in randomized clinical trials. Clinical Trials 1, 352–361.

99. Canter, Robert J., Kesmodel, Susan B., Heitjan, Daniel F., Veeramachaneni, Nirmal K., Mokadam, Nahush A., Drebin, Jeffrey A., and Fraker, Douglas L. (2005). Suppression of β-catenin by antisense oligomers augments tumor response to isolated limb perfusion in a rodent model of adenomatous polyposis coli-mutant colon cancer. Annals of Surgical Oncology 12, 733–742.

100. Gelman, Andrew, Van Mechelen, Iven, Verbeke, Geert, Heitjan, Daniel F. and Meulders, Michel (2005). Multiple imputation for model checking: Completed-data plots with missing and latent data. Biometrics 61, 74–85.

101. Ma, Guoguang, Troxel, Andrea B. and Heitjan, Daniel F. (2005). An index of local sensitivity to nonignorable dropout in longitudinal modeling. Statistics in Medicine 24, 2129–2150.

102. Zhang, Jiameng and Heitjan, Daniel F. (2005). Nonignorable censoring in randomized clinical trials. Clinical Trials 2, 488–496.

103. Zhang, Jun, Martins, Ciro R., Fansler, Zoya B., Roemer, Kristina L., Kincaid, Eric A., Gustafson, Karen S., Heitjan, Daniel F., and Clark, Douglas P. (2005). DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clinical Cancer Research 11, 6544–6549.

104. Anderson, Kristin, Jacobson, Judith S., Heitjan, Daniel F., Zivin, Joshua Graff, Hershman, Dawn, Neugut, Alfred I., and Grann, Victor R. (2006). Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Annals of Internal Medicine 144, 397–406.

105. Donovan, J. Mark, Elliott, Michael R. and Heitjan, Daniel F. (2006). Predicting event times in clinical trials when treatment arm is masked. Journal of Biopharmaceutical Statistics 16, 343–356.

106. Li, Huiling and Heitjan, Daniel F. (2006). A pattern-mixture model for the analysis of censored quality-of-life data. Statistics in Medicine 25, 1533–1546.

107. Ma, Guoguang, Troxel, Andrea B. and Heitjan, Daniel F. (2006). Authors' reply to comment on “An index of local sensitivity to nonignorable dropout in longitudinal modeling”. Statistics in Medicine 25, 3218–3220.

108. Mato, Anthony R., Riccio, Brett E., Qin, Li, Heitjan, Daniel F., Carroll, Martin, Loren, Alison, Porter, David L., Perl, Alexander, Stadtmauer, Edward, Tsai, Donald and Luger, Selina M (2006). A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leukemia and Lymphoma 47, 877–883.

109. Zhang, Jiameng and Heitjan, Daniel F. (2006). A simple sensitivity analysis tool for nonignorable coarsening: Application to dependent censoring. Biometrics 62, 1260–1268.

110. Mitra, Nandita and Heitjan, Daniel F. (2007). Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Statistics in Medicine 26, 1398–1414.

111. Sterman, Daniel H., Recio, Adri, Carrol, Richard G., Gillespie, Colin T., Haas, Andrew, Vachani, Anil, Kapoor, Veena, Sun, Jing, Hodinka, Richard, Brown, Jennifer L., Corbley, Michael J., Parr, Michael, Ho, Mitchell, Pastan, Ira, Machuzak, Michael, Benedict, William, Zhang, Xin-qiao, Lord, Elaina M., Kanther, Michelle, Litzky, Leslie A., Heitjan, Daniel F., June, Carl H., Kaiser, Larry R., Vonderheide, Robert H., and Albelda, Steven M. (2007). A phase I clinical trial of single-dose intrapleural interferon-beta gene transfer for malignant mesothelioma and metastatic pleural effusions: High rate of anti-tumor immune responses. Clinical Cancer Research 13, 4456–4466.

18

112. Donovan, J. Mark, Elliott, Michael R. and Heitjan, Daniel F. (2007). Predicting event times in clinical trials when randomization is masked and blocked. Clinical Trials 4, 481–490.

113. Zhang, Jiameng and Heitjan, Daniel F. (2007). Impact of nonignorable coarsening on Bayesian inference. Biostatistics 8, 722–743.

114. Flaherty, Keith T., Rosen, Mark A., Heitjan, Daniel F., Gallagher, Maryann L., Schwartz, Brian, Schnall, Mitchell D. and O'Dwyer, Peter J. (2008). Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biology & Therapy 147B, 712–719.

115. Haynes K, Heitjan DF, Kanetsky PA, Hennessy S (2008). Declining public health burden of digoxin toxicity from 1991 to 2004. Clinical Pharmacology and Therapeutics 84, 90–94.

116. Heitjan, Daniel F., Asch, David A., Rukstalis, Margaret, Patterson, Freda and Lerman, Caryn (2008). Cost-effectiveness of pharmacogenetic testing to tailor smoking cessation treatment. The Pharmocogenomics Journal 8, 391–399.

117. Heitjan, Daniel F., Guo, Mengye, Ray, Riju, Wileyto, E. Paul, Epstein, Leonard H. and Lerman, Caryn (2008). Identification of pharmacogenetic markers in smoking cessation therapy. The American Journal of Medical Genetics: Neuropsychiatric Genetics 147B, 712–719.

118. Schnoll, Robert A., Wileyto, E. Paul, Pinto, Angela, Leone, Frank, Gariti, Peter, Siegel, Steven, Perkins, Kenneth A., Dackis, Charles, Heitjan, Daniel F., Berrettini, Wade and Lerman, Caryn (2008). A placebo-controlled trial of modafinil for nicotine dependence. Drug & Alcohol Dependence 98, 86–93.

119. Vira, Manish A., Guzzo, Thomas, Heitjan, Daniel F., Tomaszewski, John E., D'Amico, Anthony, Wein, Alan J., and Malkowicz, S. Bruce (2008). Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known? British Journal of Urology International 101, 1232–1236.

120. Wallace, Africa, Kapoor, Veena, Sun, Jing, Mrass, Paul, Weninger, Wolfgang, Heitjan, Daniel F., June, Carl, Kaiser, Larry R., Ling, Leona E. and Albelda, Steven M. (2008). Transforming growth factor-β receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clinical Cancer Research 20, 3966–3974.

121. Wang, Hao and Heitjan, Daniel F. (2008). Modeling heaping in self-reported cigarette counts. Statistics in Medicine 27, 3789–3804.

122. Ying, Gui-shuang and Heitjan, Daniel F. (2008). Weibull prediction of event times in randomized clinical trials. Pharmaceutical Statistics 7, 107–120.

123. Carpenito, Carmine, Milone, Michael, Hassan, Raffit, Simonet, Jacqueline, Lakhal, Mehdi, Suhoski, Megan, Varela-Rohena, Angel, Haines, Kathleen, Heitjan, Daniel F., Albelda, Steven, Carroll, Richard, Riley, James, Pastan, Ira and June, Carl (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the USA 106, 3360–3365.

124. Griffith, Sandra D., Shiffman, Saul and Heitjan, Daniel F. (2009). A method comparison study of time-line follow-back and ecological momentary assessment of daily cigarette consumption. Nicotine & Tobacco Research 11, 1368–1373. doi: 10.1093/ntr/ntp150.

125. Kim, Seo Young, Guevara, James P., Kim, Kyoung Mi, Choi, Hyon K., Heitjan, Daniel F. and Albert, Daniel A. (2009). Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis Care & Research 61, 885–892.

126. Mato, Anthony R., Fuchs, Barry D., Heitjan, Daniel F., Mick, Rosemarie, Halpern, Scott D., Shah, Payal D., Jacobs, Samantha, Olson, Erin, Schuster, Steven J., Ujjani, Chaitra, Chong, Elise A., Loren, Alison W., Miltiades, Andrea N. and Luger, Selina M. (2009). Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of septic shock in hospitalized patients with hematologic malignancies. Cancer Biology & Therapy 8:12, 1–6.

127. Xie, Hui and Heitjan, Daniel F. (2009). Local sensitivity to nonignorability: Dependence on the assumed dropout mechanism. Statistics in Biopharmaceutical Research 1, 243–257.

19

128. Fridlender, Zvi G., George Buchlis, George, Kapoor, Veena, Cheng, Guanjun, Sun, Jing, Singhal, Sunil, Crisanti, M. Cecilia, Wang, Liang-Chuan S., Heitjan, Daniel, Snyder, Linda A. and Albelda, Steven M. (2010). CCL2 blockade augments cancer immunotherapy. Cancer Research 70, 109–118. doi:10.1158/0008-5472.CAN-09-2326.

129. Gastonguay, Marc R., French, Jonathan L., Heitjan, Daniel F., Rogers, James A., Ahn, Jae Eun, and Ravva, Patanjali (2010). Missing data in model-based pharmacometric applications: Points to consider. The Journal of Clinical Pharmacology 50, 63S–74S.

130. Guo, Mengye and Heitjan, Daniel F. (2010). Multiplicity-calibrated Bayesian hypothesis tests. Biostatistics 11, 473–483.

131. Kim, Seo Young, Guevara, James P., Kim, Kyoung Mi, Choi, Hyon K., Heitjan, Daniel F., and Albert, Daniel A. (2010). Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care & Research 62, 170–180.

132. Li, Yimei, Wileyto, E. Paul and Heitjan, Daniel F. (2010). Modeling smoking cessation data with alternating states and a cure fraction using frailty models. Statistics in Medicine 29, 627–638. doi:10.1002/sim.3825.

133. Mato, Anthony R., Luger, Selina, Heitjan, Daniel F., Mikkelsen, Mark E., Olson, Erin, Ujjani, Chaitra, Miltiades, Andrea N., Shah, Payal, Shuster, Stephen J., Carroll, Martin, Chauffe, Ann Duskin and Fuchs, Barry D. (2010). Elevation in serum lactate at the time of febrile neutropenia in hemodynamically-stable patients with hematologic malignancies is associated with the development of septic shock within 48 hours. Cancer Biology & Therapy 9, 583–587. (Accompanying editorial: Elstrom, Rebecca (2010). Serum lactate in febrile neutropenia. What can it tell us? Cancer Biology & Therapy 9, 588–589.)

134. Ray, Riju, Mitra, Nandita, Baldwin, Don, Guo, Mengye, Patterson, Freda, Heitjan, Daniel F., Jepson, Christopher, Wileyto, E. Paul, Wei, Jinxue, Payne, Thomas, Ma, Jennie Z., Li, Ming and Lerman, Caryn (2010). Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 35, 1374–1382.

135. Schnoll, Robert A., Patterson, Freda, Wileyto, E. Paul, Heitjan, Daniel F., Shields, Alexandra E., Asch, David A. and Lerman, Caryn (2010). A re-examination of the recommended duration of transdermal nicotine therapy for tobacco dependence: Evidence from a placebo-controlled clinical trial. Annals of Internal Medicine 152, 144–151.

136. Sterman, Daniel H., Recio, Adri, Haas, Andrew R., Vachani, Anil, Katz, Sharyn, Gillespie, Colin T., Cheng, Guanjun, Sun, Jing, Pereira, Luana, Moon, Edmund, Heitjan, Daniel F., Litzky, Leslie, June, Carl, Vonderheide, Robert, Carroll, Richard and Albelda, Steven M. (2010). A phase I clinical trial of repeated intrapleural adenoviral-mediated interferon beta gene transfer for malignant mesothelioma and metastatic pleural effusions. Molecular Therapy 18, 852–860.

137. Christofidou-Solomidou, Melpo, Tyagi, Sonia, Tan, Kay-See, Hagan, Sarah, Pietrofesa, Ralph, Dukes, Floyd, Arguiri, Evguenia, Heitjan, Daniel F., Solomides, Charalambos C. and Cengel, Keith A. (2011). Dietary flaxseed administered post-thoracic radiation treatment improves survival and mitigates radiation-induced pneumonopathy in mice. BMC Cancer 11:269. doi:10.1186/1471-2407-11-269.

138. Grann, Victor R., Patel, Priya R., Jacobson, Judith S., Warner, Ellen, Heitjan, Daniel F., Ashby-Thompson, Maxine, Hershman, Dawn and Neugut, Alfred I. (2011). Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Research & Treatment 125, 837–847. doi:10.1007/s10549-010-1043-4.

139. Li, Yimei, Wileyto, E. Paul and Heitjan, Daniel F. Prediction of individual long-term outcomes in smoking cessation trials. Biometrics 67, 1321–1329. doi:10.1111/j.1541-0420.2011.01578.x.

140. Reshef, R., Luskin, M. R., Reshef, R., Kamoun, M., Vardhanabhuti, S., Tomaszewski, J. E., Stadtmauer, E. A., Porter, D. L., Heitjan, D. F. and Tsai, D. E. (2011). Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. American Journal of Transplantation 11, 817–825; doi: 10.1111/j.1600-6143.2011.03454.x.

20

141. Reshef, Ran, Vardhanabhuti, Saran, Luskin, Marlise R., Heitjan, Daniel F., Porter, David L., Stadtmauer, Edward A. and Tsai, Donald E. (2011). Reduction of immunosuppression as initial therapy for post-transplantation lymphoproliferative disorder. American Journal of Transplantation 11, 336–347; doi:10.1111/j.1600-6143.2010.03387.x.

142. Li, Yimei and Heitjan, Daniel F. A note on the complementary mixture Pareto II distribution. In press, Communications in Statistics — Theory and Methods, 2011.04.05.

143. Li, Yimei, Wileyto E. Paul and Heitjan, Daniel F. Statistical analysis of daily smoking status in smoking cessation clinical trials. In press, Addiction, 2011.05.26.

144. Liu, Tao and Heitjan, Daniel F. Sensitivity of the discrete-time Kaplan-Meier estimate to nonignorable censoring: Application in a clinical trial. In press, Statistics in Medicine, 11.10.08.

145. Sterman, Daniel H., Haas, Andrew R., Moon, Edmund, Recio, Adriana, Schwed, Daniel, Vachani, Anil, Katz, Sharyn, Gillespie, Colin, Cheng, Guan-Jun, Sun, Jing, Papasavvas, Emmanouil, Montaner, Luis J., Heitjan, Daniel F., Litzky, Leslie, Friedberg, Joseph, Culligan, Melissa, June, Carl H., Carroll, Richard G., Albelda, Steven M. A trial of intrapleural adenoviral-mediated interferon-α2b gene transfer for malignant pleural mesothelioma. In press, American Journal of Respiratory & Critical Care Medicine, 2011.06.03.

146. Vogl, Dan T., Pérez, Waleska S., Stadtmauer, Edward A., Heitjan, Daniel F., Lazarus, Hillard M., Kyle, Robert A., Kamble, Ram, Weisdorf, Daniel, Roy, Vivek, Gibson, John, Ballen, Karen, Holmberg, Leona, Bashey, Asad, McCarthy, Philip L., Freytes, Cesar, Maharaj, Dipnarine, Maiolino, Angelo, Vesole, David and Hari, Parameswaran. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. In press, Biology of Blood and Marrow Transplantation, 11.06.02.

147. Frey, Noelle, Tizon, Richard, Heitjan, Daniel F., Tan, Kay See, Goldstein, Steven, Hexner, Elizabeth, Loren, Alison, Luger, Selina, Reshef, Ran, Tsai, Donald, Vogl, Dan, Davis, Jennifer, Vozniak, Michael, Fuchs, Barry, Stadtmauer, Edward and Porter, David. High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation. In press, Bone Marrow Transplantation, 2011.12.

Research Publications: peer-reviewed reviews: None

Contributions to peer-reviewed clinical research publications, participation cited but not by authorship: None

Research Publications, non-peer reviewed: None

Abstracts: None

Editorials, Reviews, Book Chapters, Including Participation in Committee Reports (print or other media):

1. Heitjan, Daniel F. (1990). Review of Interpreting Data by Alan J. B. Anderson. Statistics in Medicine 9, 858.

2. Heitjan, Daniel F. (1993). On the proposal to certify statisticians. Letter to the editor. Amstat News 200 (July 1993).

3. Heitjan, Daniel F. (1994). Estimation with missing data. Letter to the editor. Biometrics 50, 580. 4. Heitjan, Daniel F. (1994). The NSABP trials. Letter to the editor. New England Journal of

Medicine 331, 809–810. 5. Heitjan, Daniel F. (1996). Review of Observational Studies by Paul R. Rosenbaum. SIAM Review

21

38, 529. 6. Heitjan, Daniel F. (1997). Annotation: What can be done about missing data? Approaches to

imputation. American Journal of Public Health 87, 548–550. 7. Heitjan, Daniel F. (1998). Review of The EM Algorithm and Extensions by Geoffrey J. McLachlan

and Thriyambakam Krishnan. Statistics in Medicine 17, 1187. 8. Heitjan, Daniel F. (1998). Analysis of longitudinal binary data from multiphase sampling-

Discussion on the papers by Forster and Smith and Clayton et al. Journal of the Royal Statistical Society, Series B 60, 89–102.

9. Heitjan, Daniel F. (1998). Coarse data. Pp. 125–127 in Encyclopedia of Statistical Sciences Update Volume 2. New York: John Wiley.

10. Heitjan, Daniel F. (1998). Grouped data. In Encyclopedia of Biostatistics. New York: John Wiley.

11. Heitjan, Daniel F. (1998). Sheppard's corrections. In Encyclopedia of Biostatistics. New York: John Wiley.

12. Heitjan, Daniel F. and Ten Have, Thomas R. (1998). Missing data, types of. Pp. 408–411 in Encyclopedia of Statistical Sciences Update Volume 2. New York: John Wiley. Will also appear in Methods and Applications of Statistics in the Life and Health Sciences, edited by N. Balakrishnan.

13. Rescigno, John and Heitjan, Daniel F. (1998). Treatment of head and neck cancer. Letter to the editor. New England Journal of Medicine 339, 1330.

14. Heitjan, Daniel F. (1999). Ignorability. Pp. 347–350 in Encyclopedia of Statistical Sciences Update Volume 3. New York: John Wiley.

15. Heitjan, Daniel F. (2009). Review of Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis by Michael J. Daniels and Joseph W. Hogan. Biometrics 65, 328.

16. Heitjan, Daniel F. (2011). Biology, models and the analysis of tumor xenograft experiments. Clinical Cancer Research 17, 949–952. doi:10.1158/1078-0432.CCR-10-3279.

17. Heitjan, Daniel F. Incomplete data: What you don't know might hurt you. In press, Cancer Epidemiology, Biomarkers & Prevention, 2011.06.09.

18. Bellamy, Scarlett, Heitjan, Daniel F., Weisberg, Edmund, and Lin, Xihong (2011). Guest editor: Thomas R. Ten Have, Ph.D., M.P.H. (1958–2011). Statistics in Biosciences 3, 1–2. doi:10.1007/s12561-011-9039-0.

Books: None

Alternative Media:

1991 Program power, a set of functions in the S language for computing power and sample size in tests of the general linear hypothesis, posted to statlib (an international electronic archive of programs and data)

Patents: None